ライフサイエンスコーパス: axilla

1 response (no invasive carcinoma in breast or axilla).

2 uestions about optimal local therapy for the axilla.

3 nts without residual cancer in the breast or axilla.

4 no evidence of invasive tumor in breast and axilla.

5 e 13 achieved pCR in the breast and 6 in the axilla.

6 al complete response (pCR) in the breast and axilla.

7 iations in arm lymphatic drainage within the axilla.

8 the impact of local control measures of the axilla.

9 biopsy for patients with clinically negative axilla.

10 ared according to response in the breast and axilla.

11 invasive alternative to SLNB for staging the axilla.

12 ; P = .0029) significantly raised pCR breast/axilla.

13 vulva, perineum, inguinal creases, and left axilla.

14 ntation of compounds secreted from the human axilla.

15 uce the regrowth of lymphatic network in the axilla.

16 e with a thickened cortex in the ipsilateral axilla.

17 on the management of the clinically negative axilla.

18 ally effective in treating the node-positive axilla.

19 Corynebacterium spp. were predominant in the axilla.

20 crete lymph nodes were palpable in the right axilla.

21 depicted unsuspected metastases outside the axilla.

22 All located SLNs were in the axilla.

23 % of patients with a histologically negative axilla.

24 nizing squamous cell metastasis in the right axilla.

25 y lower doses and surgical management of the axilla.

26 ied sentinel nodes, six had a tumor-negative axilla.

27 ntense myocardial activity that obscured the axilla.

28 umber of excised LNs were calculated for the axilla (3 levels), neck (</=3 or >/=4 dissected levels),

29 S rRNA copies of bacteria was present in the axilla (4.44 +/- 0.18 log(10) copies/mul [mean +/- stand

30 ested a total of 555 specimens: 103 from the axilla, 93 from blood, 92 from conjunctiva, 54 from fore

31 h residual invasive disease in the breast or axilla after completing neoadjuvant chemotherapy and HER

32 menopausal women, surgical management of the axilla after NET, and adjuvant systemic therapy decision

33 ess or paresthesias of the medial arm and/or axilla after surgery; in 125 (82%) of these, the problem

34 iotherapy to the residual breast but not the axilla; all were prescribed tamoxifen for 5 years.

35 In a patient with a clinically negative axilla, ALND is performed primarily for staging purposes

36 elevations in dehydroepiandrosterone in the axilla and androstenedione on the forehead.

37 as predictive for prevalence of tumor in the axilla and for PET sensitivity.

38 r de-escalation of surgery in the breast and axilla and for risk-adapted post-neoadjuvant strategies.

39 temporal inconsistencies were observed with axilla and groin as compared with one instance with ante

40 temporal inconsistencies were observed with axilla and groin compared with two instances with the an

41 screening is often performed using bilateral axilla and groin composite swabs.

42 esses, nodules, and draining fistulas in the axilla and groin of young adults.

43 With PCR, 41 (80%) axilla and groin swabs and 50 (98%) anterior nares and h

44 By culture, 35 (69%) axilla and groin swabs were positive compared with 45 (8

45 Separate axilla and groin swabs, and anterior nares and hands swa

46 ) is a newly developed method of staging the axilla and has the potential to avoid an ALND in lymph n

47 n and avoidance of arm lymphatics within the axilla and its use may reduce lymphedema.

48 with the highest percent composition in the axilla and the lowest in the forearm.

49 98% of C-ECSNs had somatic fields on chest, axilla and upper back areas.

50 le number of SLNs was found (2.5 vs. 2.8 per axilla), and the concordance between isotope and dye in

51 rate, 29% microscopic foci in breast and/or axilla, and 57% gross tumor.

52 overall: 99.3% for the groin, 95.3% for the axilla, and 84.5% for the neck basins.

53 The breast, axilla, and sternum were illuminated with NIR light and

54 luded the forehead, nostrils, buccal mucosa, axilla, antecubital fossa, groin, and toe webs with sepa

55 Somatic receptive fields on chest, axilla, arm and upper back areas were found for 77/95 (8

56 ponse (pCR) score with pCR in the breast and axilla, as well as association of baseline assay-reporte

57 the SLNs and allows immediate staging of the axilla, avoiding the need to coordinate diagnostic servi

58 the treatment unit; specimens taken from the axilla, blood, conjunctiva, forehead, mouth, rectum, and

59 scesses, and/or draining tunnels in typical (axilla, breast, groin, buttock, thighs, and inframammary

60 s states that the pathological status of the axilla can be accurately predicted by determining the st

61 he advent of sentinel lymph node biopsy, the axilla can be accurately staged in patients with T1-T3,

62 This method allows axilla-conserving surgery in patients responding well to

63 rld and has revolutionised management of the axilla during the past decade.

64 e application of SLN surgery for staging the axilla following chemotherapy for women who initially ha

65 of 18 patients, 22%; P > .05) and breast and axilla (four of 30 patients, 13% v four of 18 patients,

66 "typical" European HS, mainly involving the axilla, groin, and, in women, the inframammary region.

67 (OR = 0.55; 95% CI, .42-.73; P < .001), and axilla/groin (OR = 0.57; 95% CI, .43-.75; P < .001).

68 urveillance isolates from patients confirmed axilla/groin and nare colonization; however, results of

69 d, burdens are significantly higher than for axilla/groin colonization.

70 Axilla/groin cultures were tested by polymerase chain re

71 nce cultures (sputum, perianal, arm/leg, and axilla/groin) were obtained from all patients receiving

72 Enterobacteriaceae (CRE) using nares, skin (axilla/groin), and peri-rectal swabs.

73 olonization of C. auris in nares than in the axilla/groin, and (d) predominance of the South Asia cla

74 ticipants were swabbed in the nares, throat, axilla/groin, and wound (if applicable) at baseline and

75 nal-beam radiation therapy to the breast and axilla >3 years before enrollment and ten healthy women

76 Nine (20%) of 44 axilla had histologically confirmed lymph node involveme

77 The sentinel nodes were outside the axilla in 8 percent of cases and outside of level 1 node

78 al basis and rationale for management of the axilla in clinical trials of omission of cancer surgery

79 PURPOSE OF REVIEW: The management of the axilla in early breast cancer remains controversial.

80 nts (23%; 95% CI, 12% to 37%) and breast and axilla in eight patients (17%; 95% CI, 8% to 30%).

81 100), originating from the nerve root sleeve axilla in most patients (19 of 25, 76%; 95% CI: 59, 93);

82 rrently the standard of care for staging the axilla in patients with clinical T1-T2, N0 breast cancer

83 The surgical approach of the axilla in patients with early-stage breast cancer has wi

84 surgical methods for accurately staging the axilla in patients with early-stage breast cancer have b

85 uestioned, and appropriate management of the axilla in such patients is unknown.

86 Delivering <=50 Gy to the axilla in the presence of AXT/ECE increased axillary fai

87 9mTc-HIG began to flow under the cuff to the axilla, indicating Ppump>or=Pcuff.

88 tion that leads to permanent scarring in the axilla, inframammary region, groin, and buttocks.

89 res from nasal and extranasal sites (throat, axilla, inguinal, perirectal, and chronic wound if prese

90 Failure to identify an SLN to the axilla intraoperatively occurred in 26 of 466 patients (

91 If treatment of the axilla is indicated in patients with breast cancer who h

92 When accurate preoperative staging of the axilla is needed in patients with newly diagnosed invasi

93 orable prognosis and while metastasis to the axilla is rare, it can impact treatment recommendations.

94 with a clinically and radiologically normal axilla is sentinel lymph node biopsy with a radioisotope

95 se sites included bone, liver, contralateral axilla, lung, chest wall, pelvis, and the subpectoral, s

96 The ratio of unaffected to affected axilla lymphatic velocity (1.24 +/- 0.18) was significan

97 s, and their haplotypes were correlated with axilla microbiome DNA sequencing profiles and predicted

98 e breast biopsy markers, particularly in the axilla, more sonographically visible or identifiable for

99 ging using this modified oblique view of the axilla (MOVA) started immediately after peritumoral inje

100 ks (n = 6), knees (n = 3), calf (n = 1), and axilla (n = 1).

101 m the antecubital fossa, forehead, back, and axilla of 12 male and 10 female subjects using commercia

102 ed samples from the nasal cavity, mouth, and axilla of a human subject could be successfully determin

103 juvant chemotherapy can completely clear the axilla of microscopic disease before surgery, and occult

104 Rates of pCR in the breast only and the axilla only exhibited similar differences across tumor s

105 from healthy controls were obtained from the axilla only.

106 specimens were obtained from lesional skin (axilla or groin) and nonlesional skin.

107 In patients with pCR in breast and axilla, PFS and OS rates were 100% (95% CI, inestimable)

108 occur at isolated anatomical locations (e.g. axilla, rectum, temporal artery, or oral cavity).

109 a for operative procedures of the breast and axilla, reduces postoperative nausea and vomiting, and p

110 When propulsion in the breast and axilla regions was present, the mean apparent velocities

111 decreased oral intake, the presence of a dry axilla supports the diagnosis of hypovolemia (positive l

112 However, axilla temperature, white blood cell counts and neutroph

113 agmatic-field radiotherapy not including the axilla than among those who were exposed to mantle-field

114 and prevents the recurrence of cancer in the axilla, there is a significant incidence of long-term si

115 h early breast cancer and a clinically clear axilla treated by conservative surgery, postoperative ra

116 Lymph transit time from hand to axilla, ttransit, was 9.6+/-7.2 min (mean+/-s.d.) (veloc

117 The metastatic distribution in the axilla was determined in patients with occult nodal dise

118 or more intense foci of tracer uptake in the axilla was highly predictive of axillary metastasis (78%

119 sentinel lymph node biopsy, the ipsilateral axilla was imaged with MSOT.

120 Lymph-node tissue from axilla was positive for the long-terminal repeat (33 cop

121 High-dose FDG PET of the axilla was successfully performed in 50 patients (age ra

122 Surgery, including evaluation of the axilla, was done within 6 weeks of completion of neoadju

123 Rates of pCR in both the breast and axilla were 38.2% in triple-negative, 45.4% in HER2-posi

124 thin this study population, PET scans of the axilla were interpreted with sufficient sensitivity for

125 ed definitive radiotherapy to the breast and axilla, whereas patients with residual disease underwent

126 portant issues relating to management of the axilla, which includes not only the indications and tech

127 uent identification of arm lymphatics in the axilla, which would have been transected during routine

128 o care for a tender, red papule in his right axilla with increasing induration and pain.

129 N) biopsy was adopted for the staging of the axilla with the assumption that it would reduce the risk

130 de biopsy was adopted for the staging of the axilla with the assumption that it would reduce the risk

131 ological complete response in the breast and axilla (ypT0/is ypN0) as determined by a local pathologi

132 e agents on pCR breast (ypT0/is), pCR breast/axilla (ypT0/isN0), treatment delivery, and toxicities w

133 ological complete response in the breast and axilla (ypT0/Tis, ypN0) at surgery in all randomly assig

134 men who underwent surgical evaluation of the axilla, zero of seven patients had positive nodes.